Tandem Meetings 2023 | The benefit of CAR-T therapy in second-line relapse in R/R DLBCL
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, emphasizes the importance of getting more patients with diffuse large B-cell lymphoma (DLBCL) to CAR-T therapy in the setting of second-line relapse to achieve a durable complete remission (CR). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So I think, for us, the main treatment, not only for DLBCL, but for all patients with malignancy, is to give patients the longest life with the best quality of life with a minimum amount of treatment. That really means to achieve complete remissions that are durable and preferably without any sustained maintenance therapy. So we need to remind that with large B-cell lymphoma, more than half of the patients are cured with frontline therapy...
So I think, for us, the main treatment, not only for DLBCL, but for all patients with malignancy, is to give patients the longest life with the best quality of life with a minimum amount of treatment. That really means to achieve complete remissions that are durable and preferably without any sustained maintenance therapy. So we need to remind that with large B-cell lymphoma, more than half of the patients are cured with frontline therapy. But patients who relapse, particularly if they relapse early, trying to control their disease is a challenge.
We now know that all the CD19-targeted CAR-T therapies actually are superior to platinum-based salvage treatments in the setting of second-line relapse in patients who have short remissions or failed to respond to primary induction treatment, and this is now an indication. So our goals are to try to get as many patients possible to CAR-T therapies. I think the other goal should be to find novel re-induction strategies because the reality is the randomized trials that compared CAR versus autologous transplant, we’re really comparing CAR versus salvage chemotherapy, and we know that salvage chemotherapy, traditional platinum-based treatments, in this situation, is not very good.
Read more...
Disclosures
Dr. Sergio Giralt receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson, Inc., Actinium Pharmaceuticals, Inc., and is on the Advisory Boards for: Kite Pharmaceuticals, Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson, Inc., Amgen Inc., Takeda Pharmaceutical Co., Jazz Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc.
